Table 1

Comparison of patients with SLE who never had serum NN with the rest of the group
NN-negative NN-positive P-value
(n patients = 18) (n patients = 31)
(n samples = 144) (n samples = 253)
Mean age at first sample (SD)(*) 37.7 (13.1) 34.9 (12.8) 0.47
% Female (n)(*) 77.8 (14) 83.9 (26) 0.71
Ethnicity(*) 0.41
% AC (n) 27.8 (5) 41.9 (13)
% C (n) 61.1 (11) 38.7 (12)
% Other (n) 11.1 (2) 19.3 (6)
Median anti-dsDNA IU/ml (IQR)(**) (†) 29 (13, 97) 82 (17, 171) 0.18
Mean C3 g/l (SD)(**) 1.0 (0.2) 0.9 (0.3) 0.10
Median Global BILAG score (IQR)(**) (†) 5 (2, 8) 5 (3, 10) 0.22
% anti-Sm positive (n)(*) 0.0 (0) 35.5 (11) 0.004
% anti-RNP positive (n)(*) 27.8 (5) 32.3 (10) 1.00
% anti-Ro-positive (n)(*) 38.9 (7) 45.2 (14) 0.77
% anti-La positive (n)(*) 16.7 (3) 9.7 (3) 0.66
% on hydroxychloroquine (n)(**) 42.1 (61) 44.7 (113) 0.66
% on immunosuppressants (n)(**) 25.7 (37) 63.2 (160) 0.001
% on ≥5 mg/day corticosteroids (n)(**) 68.1 (98) 78.3 (198) 0.31

(*)Analysis performed at the patient level.

(**)Analysis performed at the sample level.

(†)Statistical comparison performed on log scale.

Footnote - Global BILAG score is calculated from the formula A = 9, B = 3, C = 1, D = 0, E = 0 as described in previous papers [12]. Bold type indicates statistically significant P-values (P <0.05). BILAG, British Isles Lupus Assessment Group; NN, nitrated nucleosomes; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.

Croca et al.

Croca et al. Arthritis Research & Therapy 2014 16:R48   doi:10.1186/ar4477

Open Data